ADPT Valuation

Adaptive Biotechnologies Corp

Add to Watchlist

Advanced Chart

13.180

-0.13(-0.977%)1D

Overview
Forecast
Valuation
Earnings

ADPT Relative Valuation

ADPT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ADPT is overvalued; if below, it's undervalued.

Historical Valuation

Adaptive Biotechnologies Corp (ADPT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 7.90 is considered Undervalued compared with the five-year average of -12.61. The fair price of Adaptive Biotechnologies Corp (ADPT) is between 538.70 to 542.15 according to relative valuation methord. Compared to the current price of 13.13 USD , Adaptive Biotechnologies Corp is Undervalued By 97.56%.

Relative Value

Fair Zone

538.70-542.15

Current Price：13.13

97.56%

Undervalued

-19.97

Trailing

Forward

-78.78

EV/EBITDA

Adaptive Biotechnologies Corp. (ADPT) has a current EV/EBITDA of -78.78. The 5-year average EV/EBITDA is -18.02. The thresholds are as follows: Strongly Undervalued below -51.92, Undervalued between -51.92 and -34.97, Fairly Valued between -1.06 and -34.97, Overvalued between -1.06 and 15.89, and Strongly Overvalued above 15.89. The current Forward EV/EBITDA of -78.78 falls within the Strongly Undervalued range.

-20.56

EV/EBIT

Adaptive Biotechnologies Corp. (ADPT) has a current EV/EBIT of -20.56. The 5-year average EV/EBIT is -10.56. The thresholds are as follows: Strongly Undervalued below -30.15, Undervalued between -30.15 and -20.36, Fairly Valued between -0.77 and -20.36, Overvalued between -0.77 and 9.03, and Strongly Overvalued above 9.03. The current Forward EV/EBIT of -20.56 falls within the Undervalued range.

8.11

Adaptive Biotechnologies Corp. (ADPT) has a current PS of 8.11. The 5-year average PS is 14.18. The thresholds are as follows: Strongly Undervalued below -17.13, Undervalued between -17.13 and -1.47, Fairly Valued between 29.83 and -1.47, Overvalued between 29.83 and 45.49, and Strongly Overvalued above 45.49. The current Forward PS of 8.11 falls within the Historic Trend Line -Fairly Valued range.

-45.85

P/OCF

Adaptive Biotechnologies Corp. (ADPT) has a current P/OCF of -45.85. The 5-year average P/OCF is -16.84. The thresholds are as follows: Strongly Undervalued below -47.37, Undervalued between -47.37 and -32.10, Fairly Valued between -1.58 and -32.10, Overvalued between -1.58 and 13.68, and Strongly Overvalued above 13.68. The current Forward P/OCF of -45.85 falls within the Undervalued range.

-579.08

P/FCF

Adaptive Biotechnologies Corp. (ADPT) has a current P/FCF of -579.08. The 5-year average P/FCF is -36.87. The thresholds are as follows: Strongly Undervalued below -207.42, Undervalued between -207.42 and -122.14, Fairly Valued between 48.41 and -122.14, Overvalued between 48.41 and 133.68, and Strongly Overvalued above 133.68. The current Forward P/FCF of -579.08 falls within the Strongly Undervalued range.

Adaptive Biotechnologies Corp (ADPT) has a current Price-to-Book (P/B) ratio of 11.27. Compared to its 3-year average P/B ratio of 3.39 , the current P/B ratio is approximately 233.03% higher. Relative to its 5-year average P/B ratio of 4.64, the current P/B ratio is about 142.74% higher. Adaptive Biotechnologies Corp (ADPT) has a Forward Free Cash Flow (FCF) yield of approximately -4.19%. Compared to its 3-year average FCF yield of -18.73%, the current FCF yield is approximately -77.62% lower. Relative to its 5-year average FCF yield of -14.34% , the current FCF yield is about -70.77% lower.

11.16

P/B

Median3y

3.39

Median5y

4.64

-4.09

FCF Yield

Median3y

-18.73

Median5y

-14.34

Competitors Valuation Multiple

The average P/S ratio for ADPT's competitors is 1392.84, providing a benchmark for relative valuation. Adaptive Biotechnologies Corp Corp (ADPT) exhibits a P/S ratio of 8.11, which is -99.42% above the industry average. Given its robust revenue growth of 36.33%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ADPT.O

Adaptive Biotechnologies Corp

ANI Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

30.54

33.34%

2.04B

Performance Decomposition

Market capitalization of ADPT increased by 180.43% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -5.34 to -16.21.

The secondary factor is the Revenue Growth, contributed 36.33%to the performance.

Overall, the performance of ADPT in the past 1 year is driven by P/E Change. Which is more unsustainable.

36.33%

43.19M → 58.88M

Revenue Growth

-59.40%

-107.08 → -43.47

Margin Expansion

203.50%

-5.34 → -16.21

P/E Change

180.43%